Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Research & Development (2016 - 2025)

Viking Therapeutics' Research & Development history spans 12 years, with the latest figure at $153.5 million for Q4 2025.

  • For Q4 2025, Research & Development rose 395.24% year-over-year to $153.5 million; the TTM value through Dec 2025 reached $345.0 million, up 239.38%, while the annual FY2025 figure was $345.0 million, 239.38% up from the prior year.
  • Research & Development for Q4 2025 was $153.5 million at Viking Therapeutics, up from $90.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $153.5 million in Q4 2025 and bottomed at $9.8 million in Q4 2021.
  • The 5-year median for Research & Development is $17.3 million (2022), against an average of $30.5 million.
  • The largest annual shift saw Research & Development dropped 12.32% in 2023 before it surged 395.24% in 2025.
  • A 5-year view of Research & Development shows it stood at $9.8 million in 2021, then soared by 64.29% to $16.2 million in 2022, then increased by 26.73% to $20.5 million in 2023, then skyrocketed by 51.14% to $31.0 million in 2024, then soared by 395.24% to $153.5 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Research & Development are $153.5 million (Q4 2025), $90.0 million (Q3 2025), and $60.2 million (Q2 2025).